Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

The issuer is solely responsible for the content of this announcement.

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.87 which represents a slight increase of $0.64 or 1.10% from the prior close of $58.23. The stock opened at ...

Merck (MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension has met ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...